Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)

Home > Science Hub > Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)
Back to the list

March 3, 2026

Pierre Gontard1, Nathalie Bernard1, Sara Diels1, Bart Tegenbos1, Dirk Goossens1, Lien Heyrman1, Magdalena Stolarek-Januszkiewicz2, Sam Abujudeh2, Jurgen Del Favero1,Barnaby Balmforth2

You might also be interested by

Videos

Chats with our Scientific Advisory Board: Rupert Vessey, PhD with Christopher Ung on Drug Development

July 21, 2026

More info

Videos

Chats with our Scientific Advisory Board: Carl June, MD with Christopher Ung on Immunotherapies

July 21, 2026

More info

Videos

Chats with our Scientific Advisory Board: George Demetri, MD and Charles Sawyers, MD with Christopher Ung on Immunotherapies

July 21, 2026

More info

Press Releases

CellCarta Launches Digital Pathology and AI Consortium to Accelerate Platform-Agnostic Biomarker Innovation Across Drug Development

July 15, 2026

More info